Clinical Features and Prognosis Analysis of Hormone Receptor-Positive, HER2-Negative Breast Cancer with Differential Expression Levels of Estrogen and Progesterone Receptors: A 10-Year Retrospective Study
Open Access
- 29 November 2022
- journal article
- research article
- Published by Wiley in The Breast Journal
- Vol. 2022, 1-11
Abstract
Background. Estrogen and progesterone receptor status can predict breast cancer patient prognosis and treatment sensitivity, but research on low ER and PR levels and expression balance remains limited. Methods. From January 2010 to October 2016, 283 ER+/PR+/HER2-breast cancer patients who met the inclusion criteria were enrolled and divided into the H group (ER > 10%, N = 261) and the L group (1% ≤ ER ≤ 10%, N = 22). Groups were further divided into the HH group (ER > 10%/PR > 20%, N = 201), the HL group (ER > 10%/ER 1% ≤ PR ≤ 20% PR, N = 60), the LH group (1% ≤ ER ≤ 10%/PR > 20%, N = 5), and the LL group (1% ≤ ER ≤ 10%/1% ≤ PR ≤ 20%, N = 17). The LH group was excluded due to its small size, leaving the clinical and prognostic characteristics of 2 large groups and 3 subgroups to be analyzed. Results. L group patients had significantly more stage N2 axillary lymph nodes than H group patients (31.8% vs. 9.2%, = 0.007). Age ( = 0.011), menopause status ( = 0.001), and tumor size ( = 0.024) were significantly different in the HL vs. HH and LL groups. Five-year DFS (94.6% vs. 77.0%, < 0.001) and 5-year OS (97.2% vs. 85.8%, = 0.001) rates significantly differed between HH and HL. No significant differences in 5-year DFS (77.0% vs. 81.9%, = 0.564) or 5-year OS (85.8% vs. 87.8%, = 0.729) rates were observed between HL and LL; the OS rates of HL and LL were similar. Conclusion. In the group of ER+/PR+/HER2-patients, there was no significant prognostic difference between ER-low positive and ER-high positive groups, but low PR expression was significantly associated with a worse prognosis. The role of ER and PR balance in breast cancer progression and individualized treatment requires further investigation.Keywords
Funding Information
- Chongqing Medical University (KY2019G016)
This publication has 32 references indexed in Scilit:
- Prognostic Significance of Progesterone Receptor–Positive Tumor Cells Within Immunohistochemically Defined Luminal A Breast CancerJournal of Clinical Oncology, 2013
- Progesterone receptor loss identifies Luminal B breast cancer subgroups at higher risk of relapseAnnals of Oncology, 2012
- Survival Benefit of Tamoxifen in Estrogen Receptor-Negative and Progesterone Receptor-Positive Low Grade Breast Cancer PatientsJournal of Breast Cancer, 2012
- Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor–Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype—ACOSOG Z1031Journal of Clinical Oncology, 2011
- The oestrogen receptor-negative/progesterone receptor-positive breast tumour: a biological entity or a technical artefact?Journal of Clinical Pathology, 2008
- Molecular profiles of progesterone receptor loss in human breast tumorsBreast Cancer Research and Treatment, 2008
- Reversal of the Estrogen Receptor–Negative Phenotype in Breast Cancer and Restoration of Antiestrogen ResponseClinical Cancer Research, 2007
- Biologic and Clinical Characteristics of Breast Cancer With Single Hormone Receptor–Positive PhenotypeJournal of Clinical Oncology, 2007
- Proposal for Standardized Definitions for Efficacy End Points in Adjuvant Breast Cancer Trials: The STEEP SystemJournal of Clinical Oncology, 2007
- Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 statusAnnals of Oncology, 2006